The pulmonary route appears to be the most attractive alternative for non-invasive systemic delivery of insulin. We have shown the feasibility of insulin microcrystals as a long-acting formulation for pulmonary delivery. In this study, we examined the effects of adjuvant for pulmonary formulations of insulin, such as protamine, zinc, and glycerol. In an in vivo experiment with rats, only zinc enhanced the hypoglycemic effect of insulin microcrystals, with 17% of minimum reductions in blood glucose (%MRBG) and a 44% decrement in the blood glucose level (D% 9h ).
After the discovery of insulin in 1922 by Banting and Best, it became a leading protein therapeutic intensively researched all around the world. This also showed the promising results of systemic drug delivery via the pulmonary route. 1) For instance, inhaled insulin showed a more rapid onset of action (peak at 5-60 min) than that of subcutaneous injection (peak at 60-180 min) in human studies. In addition it showed a more ''natural'' absorption profile than other nasal, subcutaneous, or intravenous delivery routes.
2) Several companies are focusing on the development of a short-acting insulin inhaler, and some of them are in the clinical stages. 3) On the other hand, a long-acting insulin inhaler is in early stages of development. Up to now, a few groups have tried to develop long-acting insulin formulations, using lipid co-administration 4) or porous particles, 5) but there are limitations, such as biopolymer accumulation in the lung and the requirement of a large drug mass for human applications. 2) Recently, a unique insulin microcrystallization process using a seed zone method was developed, and a patent has been filed. 6, 7) Using this preparation, we showed the feasibility of insulin microcrystals as a longacting inhaler formulation. 8) Briefly, microcrystals administered by intratracheal instillation to diabetic rats showed lower blood glucose levels over 13 h as compared to an insulin solution. In case of intratracheal inhalation, there were significant glucose reductions over 7 h (P < 0:05 by unpaired t-test). These results show that insulin microcrystals are promising as a sustained release formulation for pulmonary delivery.
In our pervious studies, however, no supplements were added to the insulin formulation. In fact, many kinds of adjuvants are added to commercial insulin dosage forms intended for injection.
Hence, in this study, we examined the effects of adjuvants which are currently used in injection formulations, such as protamine, zinc, and glycerol, on the hypoglycemic effect of insulin microcrystals delivered by the pulmonary route.
Insulin from bovine pancreas (Sigma, St. Louis, USA) was purchased, and microcrystals were prepared by the seed zone method. 9) Briefly, insulin (1 mg/ml) was completely dissolved in 0.1 N acetic acid (pH 2.0), and the acidity of the solution was increased stepwise with additions of NaOH. When the pH reached 10.5 (seed zone), it was carefully re-adjusted to 6.0 with 5 N HCl. After stirring for 15 min, the microcrystals were stored at 4 C pending additional experimentation. Insulin microcrystals were collected by centrifugation at 10,000 rpm for 10 min (Eppendorf 5804R, Hamburg, Germany). The supernatant was discarded and dosing formulations containing insulin and adjuvant were prepared in saline at pH 6.0. The final concentrations of insulin and adjuvant were adjusted to 1 mg/ml of insulin and each predetermined concentration of adjuvant respectively.
Male Sprague-Dawley rats, weighing 200-250 g, were fasted for 12-18 h prior to the experiment, while water was allowed ad libitum. The rats were anesthetized with an intraperitoneal injection of ketamine (60 mg/kg) and sodium pentobarbital (20 mg/kg), and placed ventral side up on a surgical table provided with a temperaturecontrolled pad to maintain physiological temperature. After their tracheas were surgically exposed, insulin formulations (volume, 100 ml) were administered into the lungs using a microsyringe (1725LT, Hamilton, NV, USA). After administration, the necks were sutured and the rats were revived within 2 h. Blood samples were withdrawn from the tail vein at appropriate time intervals and the blood glucose concentration was y To whom correspondence should be addressed. Tel: +82-2-3290-3439; Fax: +82-2-3290-3957; E-mail: cwkim@korea.ac.kr Biosci. Biotechnol. Biochem., 70 (4), [1003] [1004] [1005] 2006 Note determined by the glucose oxidase method. Decrements of the blood glucose level (D% Xh ) were calculated by the following equation 10) (here, the area above the 100% line was ruled out for calculating the AUC 0-Xh ): Table 1 shows pharmacodynamic profiles of insulin microcrystals in the presence of various adjuvants. When the insulin microcrystal suspension (5 U/kg, pH 6.0) alone were administered without an adjuvant, %MRBG and D% was 66% and 9.8%, respectively.
In the presence of glycerol, there was a little change in blood glucose profiles. The time of minimum blood glucose changed to 3 or 5 h after administration, but D% did not change significantly.
Protamine, a highly basic polypeptide, is known to protract the release of free insulin from the crystal matrix.
11) In our experiment, however, %MRBG, D%, and the time at minimum blood glucose did not differ significantly from the control (insulin microcrystal alone). These results can be explained in terms of different molecular interactions between insulin and protamine. In the commercial injection formulations, protamine usually presents as cocrystalline complexes with insulin, and this cocrystalline suspension is administered to a patient subcutaneously, resulting in a protracted release of free insulin. In our formulation, a simple mixture of insulin microcrystals and free protamine in solution was used. In this mixture, most of the protamine is presents as a free molecule not a cocrystalline form with insulin. Therefore, the protracting effect of protamine diminished in our experiment.
As shown in Table 1 , at a low zinc concentration (25 mg/ml, ZnCl 2 ), there were no significant changes in the blood glucose level as compared to the control. At a high concentration of zinc (250 mg/ml, ZnCl 2 ), however, a significant hypoglycemic effect was observed as compared with insulin mycrocrystals alone. The percentage of minimum reductions in blood glucose (%MRBG) was 17%, and the decrement in the blood glucose level (D%) reached 44% during the 9 h after administration (P < 0:01 by unpaired t-test).
To clarify the effect of zinc on enhancement of the hypoglycemic effect, we examined various zinc concentrations with a high insulin dose (10 U/kg). Figure 1 shows concentration-time profiles of the glucose in blood after intratracheal instillation of an insulin microcrystal suspension in the presence of zinc. The blood glucose level was influenced by the amount of zinc coadministered with insulin microcrystals. In the absence of zinc, the minimum reduction in blood glucose (%MRBG) and the decrement in blood glucose level (D%) were 44% and 37% respectively. In the presence of zinc, %MRBG decreased to 36-24% and D% increased to 43-48%, which demonstrates the enhanced hypoglycemic effect. The higher the concentration of zinc chloride, the lower the %MRBG and the higher the D% observed (Table 2) . At a high zinc chloride concentration (400 mg/ml), all the rats were dead within 5 h after administration because of low blood glucose levels, although the same amount of insulin microcrystals (10 U/kg) was administered.
Zinc ion is an essential supplement in the human diet and its involvement in the regulation of numerous The same volume (100 ml) of saline or insulin microcrystal suspension with various zinc chloride concentrations was administered. , Saline only; , Microcrystal only (10 U/kg); , (+) ZnCl 2 50 mg/ml; , (+) ZnCl 2 100 mg/ml; , (+) ZnCl 2 200 mg/ ml; , (+) ZnCl 2 400 mg/ml. The glucose concentration is expressed as a percentage value at time zero. The error bar represents S.E.M. for four or five rats. 12, 13) Glucose uptake increased 2 to 3 times in the presence of 1 to 20 mM ZnCl 2 in in vitro study with adipocytes. 12) In addition, the blood glucose level decreased from 400 to 250 mg/dl with daily intraperitoneal injections of ZnCl 2 (3 mg/kg body weight) in an in vitro study with mice. 13) This clearly demonstrates the insulin-like action of zinc, but the concentration of zinc complex injection was 3 mg/kg, 30 to 150 times higher than in our study (0.02 to 0.1 mg/kg). Therefore, we think that the insulin-like action of zinc ion in our study might be minimal in the concentration range of zinc that we studied.
Furthermore, the zinc ion is the basic supporter in the insulin microcrystal structure, and prolongs the collapse of insulin crystals from polymers (usually hexamers) to monomers which can be absorbed in body. Zinc is known to enhance the stability of insulin crystal structure through the formation of zinc-containing hexamers. 14) Using zinc chloride as an adjuvant has an advantage over other supplements because zinc ion originally is a major material used in the microcrystallization of insulin by the seed zone method.
With respect to insulin and zinc, early studies recognized that the protracted effect of insulin preparation can be obtained by the addition of small amounts of zinc ions. It was also shown that the crystalline form of insulin has prolonged protraction at the same zinc concentration as compared to amorphous insulin particles. 15) Insulin zinc crystals have been used in long-acting injection formulations for glucose control, but the crystals used in these formulations are too large (up to 20 mm in diameter) to be inhaled deeply into the lungs.
2) Our previous study demonstrated the feasibility of insulin microcrystals as a sustained release formulation for pulmonary delivery. 8) In this study, we showed that zinc is promising as an adjuvant in the insulin microcrystal formulation for pulmonary delivery. Further studies are needed to verify the safety of zinc for the insulin microcrystal formulation as a pulmonary application.
